SCHEMBL5119957

SCHEMBL5119957

O=C(O)c1cccc(NC(=O)c2cc(Cl)ccc2NS(=O)(=O)c2ccc(Cl)cc2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC10A6 Q3KNW5 2/20 0.60
SLC10A2 Q12908 1/20 0.60
SLC10A1 Q14973 1/20 0.60
PPARG P37231 2/20 0.60
NR1H4 Q96RI1 2/20 0.60
PPARD Q03181 1/20 0.60
KCNA5 P22460 1/20 0.58
MEN1 O00255 4/20 0.58
KMT2A Q03164 4/20 0.58
LMNA P02545 2/20 0.56
HTT P42858 2/20 0.56
GPR27 Q9NS67 3/20 0.55
WDR5 P61964 1/20 0.55
ALDH1A1 P00352 1/20 0.55
MAPT P10636 1/20 0.55
AVPR2 P30518 1/20 0.55
CCR9 P51686 1/20 0.54
POLB P06746 1/20 0.54
CASP3 P42574 1/20 0.53
SENP8 Q96LD8 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6862493 0.96 PPARG (0.60) SLC10A6SLC10A2SLC10A1PPARGNR1H4
SCHEMBL5125608 0.91 LMNA (0.63) SLC10A6SLC10A2SLC10A1KCNA5MEN1
SCHEMBL5126770 0.90 SLC10A6 (0.67) SLC10A6SLC10A2SLC10A1KCNA5MEN1
SCHEMBL5124913 0.88 SLC10A6 (0.57) SLC10A6SLC10A2SLC10A1KCNA5MEN1
SCHEMBL6862400 0.87 SLC10A6 (0.71) SLC10A6SLC10A2SLC10A1KCNA5MEN1
SCHEMBL5115547 0.85 SMN1; SMN2 (0.64) SLC10A6SLC10A2SLC10A1KCNA5MEN1
SCHEMBL5118820 0.85 LMNA (0.58) SLC10A6SLC10A2SLC10A1KCNA5MEN1
SCHEMBL6754585 0.84 SLC10A6 (0.81) SLC10A6SLC10A2SLC10A1KCNA5MEN1
SCHEMBL491680 0.84 SLC10A6 (0.60) SLC10A6SLC10A2SLC10A1KCNA5MEN1
SCHEMBL492519 0.84 SLC10A6 (0.60) SLC10A6SLC10A2SLC10A1KCNA5MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7351703-B2 Sulfonylamino carboxylic acid N-arylamides as guanylate cyclase activators SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-04-01 US disclosed
EP-1095015-B1 SULFONYLAMINO CARBOXYLIC ACID N-ARYLAMIDES AS GUANYLATE CYCLASE ACTIVATORS AVENTIS PHARMA GMBH (DE) 2005-06-01 EP disclosed
US-20050080073-A1 Sulfonylaminocarboxiylic acid N-arylamides as guanylate cyclase activators AVENTIS PHARMA DEUTSCHLAND GMBH 2005-04-14 US disclosed
US-6809089-B2 FOR THERAPY AND PROPHYLAXIS OF CARDIOVASCULAR DISORDERS SUCH AS HIGH BLOOD PRESSURE, ANGINA PECTORIS, CARDIAC INSUFFICIENCY, THROMBOSES OR ATHEROSCLEROSIS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-10-26 US disclosed
US-20030171352-A1 Sulfonylaminocarboxylic acid N-arylamides as guanylate cyclase activators AVENTIS PHARMA DEUTSCHLAND GMBH 2003-09-11 US disclosed
US-6548547-B1 Cardiovascular disorders; hypotensive agents, antiasthmatics, cognition activators AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080073-A1 Sulfonylaminocarboxiylic acid N-arylamides as guanylate cyclase activators GUCY1A1, GUCY1B1, GUCY1A2 SLC10A6 2987/4885SLC10A2 1391/4885SLC10A1 1242/4885
US-20030171352-A1 Sulfonylaminocarboxylic acid N-arylamides as guanylate cyclase activators GUCY1A1, GUCY1B1, GUCY1B2 SLC10A6 3299/4885SLC10A2 1534/4885SLC10A1 1366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.